WealthShield Partners LLC Has $572,000 Stake in Pfizer Inc. (NYSE:PFE)

WealthShield Partners LLC grew its stake in Pfizer Inc. (NYSE:PFE) by 5.2% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 20,433 shares of the biopharmaceutical company’s stock after acquiring an additional 1,001 shares during the quarter. WealthShield Partners LLC’s holdings in Pfizer were worth $572,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Olistico Wealth LLC acquired a new position in shares of Pfizer in the 2nd quarter valued at approximately $25,000. MFA Wealth Advisors LLC bought a new position in shares of Pfizer during the second quarter worth about $29,000. Creekmur Asset Management LLC bought a new stake in Pfizer in the 4th quarter valued at approximately $32,000. Trivant Custom Portfolio Group LLC boosted its position in Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares during the last quarter. Finally, Financial Connections Group Inc. acquired a new stake in shares of Pfizer in the second quarter valued at approximately $34,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and lifted their target price for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. UBS Group upped their price target on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Morgan Stanley lifted their price objective on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. Wells Fargo & Company boosted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Finally, Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Eight research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Stock Performance

Shares of PFE traded down $0.09 during midday trading on Wednesday, reaching $28.73. 13,668,722 shares of the stock were exchanged, compared to its average volume of 38,578,496. The stock’s 50 day simple moving average is $28.89 and its 200 day simple moving average is $27.98. The company has a market cap of $162.80 billion, a P/E ratio of -483.67, a PEG ratio of 0.98 and a beta of 0.69. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $36.94. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. The business had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business’s revenue was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.67 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.68 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. The ex-dividend date is Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a yield of 5.85%. Pfizer’s dividend payout ratio (DPR) is presently -2,800.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.